<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1787">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05137899</url>
  </required_header>
  <id_info>
    <org_study_id>OCOG-2021-ADVANCE HCC ML42545</org_study_id>
    <nct_id>NCT05137899</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy</brief_title>
  <acronym>ADVANCE HCC</acronym>
  <official_title>Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy Prior to Hepatectomy in Hepatocellular Carcinoma With Portal Vein Tumour Thrombus (ADVANCE HCC) Hoffmann La Roche Protocol Number: ML42525</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre, parallel group, randomized controlled Phase II clinical trial evaluating&#xD;
      neoadjuvant Atezolizumab/Bevacizumab versus neoadjuvant SBRT in patients with biopsy proven&#xD;
      solitary HCC with PVTT involving the portal vein branches. Both arms are considered&#xD;
      experimental, and as such, a Simon two-stage design will be initially used within both arms.&#xD;
      Only if both arms are deemed of interest for further study will a comparison between arms,&#xD;
      using a pick-the-winner design, be conducted. Following the completion of neoadjuvant&#xD;
      therapy, study participants will undergo a CT scan or MRI to assess tumour response to&#xD;
      neoadjuvant therapy. Hepatic resection will be performed for those participants who meet the&#xD;
      surgical resection criteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgical resection without adjuvant therapy is the standard of care for most patients with&#xD;
      solitary hepatocellular carcinoma (HCC). The presence of portal vein tumour thrombus (PVTT)&#xD;
      is associated with a poor prognosis, and as a result patients usually do not undergo&#xD;
      surgery.1 One potential strategy to improve the outcome of patients with HCC and PVTT is to&#xD;
      administer treatment to the tumour prior to surgery, i.e. &quot;neoadjuvant&quot; therapy. This&#xD;
      strategy has been proven to be effective in other types of cancer, and results in tumour&#xD;
      downstaging and potentially eliminates micro-metastatic disease In a recent randomized&#xD;
      controlled trial (RCT) in patients with HCC and PVTT, the addition of radiation therapy (RT)&#xD;
      to the tumour prior to hepatic surgery was compared with surgery alone.4 There was a&#xD;
      statistically significant improvement in survival with RT. Systemic therapy with the tyrosine&#xD;
      kinase inhibitor Sorafenib improved survival compared to placebo in patients with advanced&#xD;
      HCC and PVTT.5 Another recent trial in patients with advanced HCC demonstrated improved&#xD;
      survival with the combination of Atezolizumab, an immune checkpoint inhibitor (ICI), and&#xD;
      Bevacizumab, an antibody to vascular endothelial growth factor compared to Sorafenib alone.6&#xD;
&#xD;
      Currently, there is no standard of care for the neoadjuvant treatment of solitary HCC.&#xD;
      Radiotherapy has not been widely adopted despite recent evidence suggesting some benefit. It&#xD;
      is conceivable that RT will downsize the tumour increasing the surgical resection rate and&#xD;
      reducing the shedding of tumour cells. Stereotactic Body Radiation Therapy (SBRT) is a type&#xD;
      of RT that provides high dose, focal radiation to tumours using highly precise imaging and&#xD;
      treatment fields, with rapid dose fall-off thereby sparing normal tissue. Based on experience&#xD;
      in other cancers, it would seem judicious that effective systemic therapy be considered for&#xD;
      the neoadjuvant treatment of HCC to downsize the primary tumour and eradicate occult&#xD;
      micro-metastases.2,3&#xD;
&#xD;
      We hypothesize that treating patients with HCC and PVTT with either 1) neoadjuvant systemic&#xD;
      therapy, or 2) neoadjuvant SBRT may lead to improved hepatic resection rates. Complete&#xD;
      hepatic resection is being considered as a surrogate for good long-term outcomes. The aim of&#xD;
      our randomized Phase II trial is to select the treatment arm with the most favourable&#xD;
      outcomes based on a trade-off between resection rate and toxicity for study in a future&#xD;
      trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 30, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Neoadjuvant Atezolizumab/Bevacizumab versus neoadjuvant SBRT in patients with biopsy proven solitary HCC with PVTT involving the portal vein branches.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatectomy</measure>
    <time_frame>17 Weeks</time_frame>
    <description>Proportion of patients who undergo hepatectomy in each arm (number of patients who undergo hepatectomy divided by the number of patients randomized to each arm).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>2 years</time_frame>
    <description>Radiological and pathological response rate to neoadjuvant therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity to SBRT</measure>
    <time_frame>2 years</time_frame>
    <description>Toxicity rate related to neoadjuvant SBRT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>90 days post operatively</time_frame>
    <description>Postoperative complication rate and mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Progression Free</measure>
    <time_frame>2 years</time_frame>
    <description>Progression free survival (PFS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival (OS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity to Atezolizumab/Bevacizumab</measure>
    <time_frame>2 years</time_frame>
    <description>Toxicity to Atezolizumab/Bevacizumab in the neoadjuvant setting</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Portal Vein Tumour Thrombosis</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Atezolizumab/Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Arm 1: neoadjuvant atezolizumab 1200 mg IV q3weeks x 4 cycles, and bevacizumab 15 mg/kg IV q3weeks x 4 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• Arm 2: neoadjuvant stereotactic body radiation therapy (SBRT), target volume 30 40 Gy, in 6-8 Gy per day over five days, delivered every other day</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Neoadjuvant</intervention_name>
    <description>Neoadjuvant atezolizumab/bevacizumab or neoadjuvant SBRT prior to hepatectomy</description>
    <arm_group_label>Neoadjuvant Atezolizumab/Bevacizumab</arm_group_label>
    <arm_group_label>Neoadjuvant SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Biopsy proven solitary HCC without biliary invasion, or metastases,&#xD;
&#xD;
          2. PVTT involving the portal vein branches: Vp1-Vp3 (Japanese Classification for HCC with&#xD;
             PVTT, see Appendix II),&#xD;
&#xD;
          3. &lt;10 cm maximal diameter on CT or MRI,&#xD;
&#xD;
          4. Child-Pugh Class A (see Appendix III), within 14 days prior to randomization. (All&#xD;
             parameters without transfusion within 3 months).&#xD;
&#xD;
          5. Age &gt; 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Abnormal laboratory parameters (within 14 days of randomization):&#xD;
&#xD;
               1. Hemoglobin &lt; 90 g/L&#xD;
&#xD;
               2. Platelet count &lt; 75 x 109/L without transfusion&#xD;
&#xD;
               3. INR &gt;1.25&#xD;
&#xD;
               4. Serum creatinine &gt; 1.5 x ULN&#xD;
&#xD;
               5. Urine dipstick for proteinuria &gt; 2 (unless a 24-hour urine collection&#xD;
                  demonstrates &lt; 1.5 g of protein in 24 hours.&#xD;
&#xD;
          2. Previous therapy for HCC:&#xD;
&#xD;
               1. Systemic therapy, surgery or radiation therapy,&#xD;
&#xD;
               2. Local therapy to the liver (e.g., ablation or embolization) within 28 days prior&#xD;
                  to randomization.&#xD;
&#xD;
          3. ECOG performance status &gt; 2 (see Appendix IV).&#xD;
&#xD;
          4. Non-healing wound, skin ulcers, or incompletely healed bone fracture.&#xD;
&#xD;
          5. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to planned start of study therapy.&#xD;
&#xD;
          6. History of bleeding from esophageal and/or gastric varices or high risk of bleeding&#xD;
             from varices seen on endoscopy (normal EGD required within 6 months of randomization).&#xD;
&#xD;
          7. History of GI perforation, abdominal fistulae, or intra-abdominal abscess.&#xD;
&#xD;
          8. Significant cardiovascular disease:&#xD;
&#xD;
               1. New York Heart Association cardiac disease (Class II or greater),&#xD;
&#xD;
               2. Myocardial infarction, unstable angina or cerebrovascular accident within past 3&#xD;
                  months,&#xD;
&#xD;
               3. Unstable arrhythmia,&#xD;
&#xD;
               4. Poorly controlled arterial hypertension (defined as systolic blood pressure (BP)&#xD;
                  &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg) based on an average of &gt; 3&#xD;
                  BP readings on &gt; 2 sessions), or prior history of hypertensive crisis or&#xD;
                  hypertensive encephalopathy,&#xD;
&#xD;
               5. Aortic aneurysm requiring surgical repair or recent peripheral arterial&#xD;
                  thrombosis within 6 months prior to randomization&#xD;
&#xD;
          9. Known contraindication to Bevacizumab or Immune Checkpoint Inhibitor (ICI): Active or&#xD;
             history of autoimmune disease or immune deficiency, including, but not limited to&#xD;
             myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus,&#xD;
             rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome,&#xD;
             Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple&#xD;
             sclerosis, autoimmune hypophysitis, or autoimmune pancreatitis. Includes known&#xD;
             hypersensitivity to any component of Bevacizumab; Chinese hamster ovary cell products&#xD;
             or other recombinant human or humanized antibodies. Known hypersensitivity to&#xD;
             Atezolizumab or any of the excipients. (Note: Patients with a history of&#xD;
             autoimmune-related hypothyroidism who are on thyroid-replacement hormone and those&#xD;
             with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible&#xD;
             for the study).&#xD;
&#xD;
         10. Known history of (Human immunodeficiency virus (HIV), HBV and HCV co-infection). For&#xD;
             patients with active HBV: HBV DNA &lt;500IU/mL obtained within 28 days prior to&#xD;
             randomization and anti-HBV treatment (per local standard of care, e.g., entecavir) for&#xD;
             a minimum of 14 days prior to study entry and willingness to continue treatment for&#xD;
             the length of the study.&#xD;
&#xD;
         11. Severe infection within 4 weeks prior to initiation of study treatment, including, but&#xD;
             not limited to, hospitalization for complications of infection, bacteremia, or severe&#xD;
             pneumonia.&#xD;
&#xD;
         12. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis&#xD;
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of&#xD;
             active pneumonitis.&#xD;
&#xD;
         13. Active tuberculosis.&#xD;
&#xD;
         14. Prior allogeneic stem cell or solid organ transplantation.&#xD;
&#xD;
         15. Treatment with systemic immunostimulatory agents (including, but not limited to,&#xD;
             interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug&#xD;
             (whichever is longer) prior to initiation of study treatment.&#xD;
&#xD;
         16. Recent administration of live vaccine.&#xD;
&#xD;
         17. History of malignancy other than HCC within 5 years prior to screening, with the&#xD;
             exception of adequately treated carcinoma in situ of the cervix, non-melanoma skin&#xD;
             carcinoma, localized prostate cancer, ductal carcinoma in situ of breast, or Stage I&#xD;
             uterine cancer.&#xD;
&#xD;
         18. Treatment with strong CYP3A4 inducers within 14 days prior to randomization.&#xD;
&#xD;
         19. Treatment with an immunosuppressive medication (including, but not limited to,&#xD;
             corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and&#xD;
             anti-TNF-α agents) within 14 days prior to randomization, or anticipation of need for&#xD;
             systemic immunosuppressive medication during study treatment, with the following&#xD;
             exceptions: a) patients who received acute, low-dose systemic immunosuppressant&#xD;
             medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48&#xD;
             hours of corticosteroids for a contrast allergy), or b) patients who received&#xD;
             mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive&#xD;
             pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic&#xD;
             hypotension or adrenal insufficiency.&#xD;
&#xD;
         20. Current or recent (within 7 days of randomization) use of aspirin (325mg/day),&#xD;
             dipyramidole, ticlopidine, clopidogrel, or cilostazol, Vitamin K antagonists, direct&#xD;
             oral anticoagulants (DOACs), LMWH.&#xD;
&#xD;
         21. Recent history (within 4 weeks) of hemoptysis.&#xD;
&#xD;
         22. History of TIA, CVA, or any arterial thrombotic event within 12 months before&#xD;
             randomization.&#xD;
&#xD;
         23. Sensory/motor neuropathy greater than or equal to grade 2, as defined by the NCI CTCAE&#xD;
             and history of hypomagnesemia.&#xD;
&#xD;
         24. Known severe allergic reaction to contrast (e.g., anaphylaxis).&#xD;
&#xD;
         25. Pregnancy or lactating women.&#xD;
&#xD;
         26. Inability to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandon Meyers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>principle investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jim Wright, MD</last_name>
    <role>Study Director</role>
    <affiliation>OCOG Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Rudd-Scott, RN BScN MN</last_name>
    <phone>905-527-2299</phone>
    <phone_ext>43793</phone_ext>
    <email>ruddl@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin McGean</last_name>
    <phone>905-527-2299</phone>
    <phone_ext>4256</phone_ext>
    <email>mcgeane@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Brandon Meyers, MD</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>64609</phone_ext>
      <email>meyersbr@hhsc.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>December 14, 2021</last_update_submitted>
  <last_update_submitted_qc>December 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant Atezolizumab/Bevacizumab</keyword>
  <keyword>Neoadjuvant Stereotactic Body Radiation Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

